

Table (1): Patient Baseline Characteristics

	Dox	Ida	P value	Test Used
Total number	120 (100%)	124 (100%)		
Male	68 (56.6%)	64 (51.6%)	0.6	Chi square
Age: Mean (SD) years	37.48 (11.5)	40.2 (11.7)	0.068	t- test
Weight: Mean (SD) kg	72 (16)	72 (15)	1	t- test
Height: Mean (SD) cm	165 (8)	164 (9)	0.36	t- test
Mutated FLT 3	14	9	0.283	Chi square
Inv (16) (+ve)	5	3	0.458	Chi square
Trans (8,21) (+ve)	10	7	0.4	Chi square
FAB Classification:			NA	
M0	4	1		
M1	40	37		
M2	34	39		
M4	33	31		
M5	5	9		
M6	1	1		
M7	3	6		

Dox: Doxorubicin, **Ida:** Idarubicin, **Pt:** Patients, **SD:** Standard Deviation, **kg:** Kilograms, **cm:** centimeters, **Inv (16):** Inversion (16), **+ve:** Positive, **Trans (8,21):** Translocation (8,21), **FAB Classification:** The French-American-British classification of AML

Table (2): Response to Treatment

Item	Dox	Ida	P value*
Total number	120 (100%)	124 (100%)	
CR	63 (52.5%)	61 (49.2%)	0.6
PR	9 (7.5%)	8 (6.4%)	0.7
RD	6 (5%)	14 (11.2%)	0.07
Responsive (CR+PR)	72 (60%)	69 (55.6%)	0.4
No CR (PR+RD)	15 (12.5%)	22 (18%)	0.3

No blasts in D14	72 (60%)	65 (52.4%)	0.2
Mortality	42 (35%)	41 (33%)	0.7

*: Using Chi square test

Dox: Doxorubicin, **Ida:** Idarubicin, **CR:** Complete remission, **PR:** Partial remission, **RD:** Refractory disease, **D14:** Day 14 of starting treatment

Table (3): Treatment Related Toxicities

Item	Dox	Ida	P value ⁽¹⁾
Total number	120 (100%)	124 (100%)	
Vomiting	59 (49%)	63 (50.8%)	0.4
OM	85 (70.8%)	46 (37%)	0.0001*
Diarrhea	66 (55%)	74 (59.6%)	0.2
Piles	25 (20.8%)	33 (26.6%)	0.18
Constipation	26 (21.6%)	22 (17.7%)	0.27
Renal abnormalities	31 (25.8%)	28 (22.5%)	0.3
Hepatic dysfunction	54 (45%)	62 (50%)	0.25
Typhlitis	13 (10.8%)	12 (9.6%)	0.4
Febrile Neutropenia	119 (99.1%)	122 (98.3%)	0.29
Invasive fungal infection	90 (75%)	110 (88.7%)	0.004*
Viral Infection	56 (46.6%)	48 (38.7%)	0.12

*: Statistically significant

(1): Using Chi square test

Dox: Doxorubicin, **Ida:** Idarubicin, **OM:** Oral mucositis

Table (4): Other Outcomes

Item	Dox	Ida	P value	Test Used
Total number	120 (100%)	124 (100%)		
TPN	43 (35.8%)	23 (18.5%)	0.0019*	Chi square
Plt				
Mean (SD) for plt units used	9 (5.9)	7.9 (5.2)	0.13	t- test
% Patients need plt transfusion	117 (97.5%)	123 (99.1%)	0.29	Chi square

Packed RBCs

Mean (SD) for RBCs units used	5.7 (3.7)	6 (3.6)	0.6	t- test
% Patients need RBCs transfusion	116 (96.6%)	122 (98.3%)	0.3	Chi square
LOS Mean (SD) days	27 (11.45)	27.89 (10.79)	0.5	t- test
Number of Patients admitted to ICU	23 (19%)	30 (24%)	0.3	Chi square

*: Statistically significant

Dox: Doxorubicin, **Ida:** Idarubicin, **TPN:** Need for parenteral nutrition, **Plt:** Platelets, **RBCs:**

Red blood cells, **LOS:** Length of hospital stay, **SD:** Standard deviation, **ICU:** Intensive care unit

Table (5): Different Costs in Dox and Ida Treatment Groups

Cost of:	Dox	Ida
Antibiotics	10464	13061
Antifungals	5608	5914
TPN	904	578
G-CSF	183	141
Chemotherapy	787	4369
Blood products	8223	7457
Lab tests	4355	4534
Radiology	1490	1504
Hospital stay	2707	2789
ICU stay	292	276

All costs in Egyptian pounds

Dox: Doxorubicin, **Ida:** Idarubicin, **TPN:** total parenteral nutrition, **G-CSF:** growth colony stimulating factor,

ICU: intensive care unit